Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection
1
School of Health Sciences, and State Key Laboratory of Virology, Wuhan University, Wuhan 430071, China
2
Fudan University School of Medicine, Shanghai 200032, China
*
Author to whom correspondence should be addressed.
Viruses 2018, 10(12), 680; https://doi.org/10.3390/v10120680
Received: 19 November 2018
/
Revised: 28 November 2018
/
Accepted: 29 November 2018
/
Published: 30 November 2018
(This article belongs to the Special Issue MERS-CoV)
Since emerging in 2012, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has been a global public health threat with a high fatality rate and worldwide distribution. There are no approved vaccines or therapies for MERS until now. Passive immunotherapy with neutralizing monoclonal antibodies (mAbs) is an effective prophylactic and therapeutic reagent against emerging viruses. In this article, we review current advances in neutralizing mAbs against MERS-CoV. The receptor-binding domain (RBD) in the spike protein of MERS-CoV is a major target, and mouse, camel, or human-derived neutralizing mAbs targeting RBD have been developed. A major problem with neutralizing mAb therapy is mutant escape under selective pressure, which can be solved by combination of neutralizing mAbs targeting different epitopes. Neutralizing mAbs are currently under preclinical evaluation, and they are promising candidate therapeutic agents against MERS-CoV infection.
View Full-Text
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Han, H.-J.; Liu, J.-W.; Yu, H.; Yu, X.-J. Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection. Viruses 2018, 10, 680. https://doi.org/10.3390/v10120680
AMA Style
Han H-J, Liu J-W, Yu H, Yu X-J. Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection. Viruses. 2018; 10(12):680. https://doi.org/10.3390/v10120680
Chicago/Turabian StyleHan, Hui-Ju, Jian-Wei Liu, Hao Yu, and Xue-Jie Yu. 2018. "Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection" Viruses 10, no. 12: 680. https://doi.org/10.3390/v10120680
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
